ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

Conditions:   Triple Negative Breast Cancer;   Endometrial Cancer;   Hormone Receptor Positive, HER2 Negative Breast Cancer Intervention:   Drug: ONC201 Sponsor:   National Cancer Institute (NCI) Recruiting

Source: ClinicalTrials.gov - January 9, 2018 Category: Research Source Type: clinical trials